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We investigated the effectiveness and safety of a dual 
therapy (DT) with lamivudine plus dolutegravir versus 
a single tablet regimen (STR) with abacavir/lamivu-
dine/dolutegravir. We performed a retrospective analy-
sis in a cohort of virologically suppressed HIV+ patients 
switching to lamivudine-dolutegravir or abacavir/
lamivudine/dolutegravir. We evaluated the incidence 
of virological failure and treatment discontinuation, as 
well as their predictors. Non-parametric tests were ap-
plied to assess changes in immunological and metabolic 
parameters. 
In all, 616 patients were analyzed: 380 began STR and 
236 DT. In the STR group three patients experienced 
VF; in the DT group seven patients experienced VF. No 
differences in cause of treatment discontinuation were 
found. The estimated probability of continuing therapy 
at 48 weeks were 88.5 % in DT and 90.3% in STR, with-
SUMMARY
out a statistically significant difference (Log-rank 0.338). 
Regarding the metabolic profile, in the STR group there 
was a reduction in LDL cholesterol levels at week 48 
(p=0.008), whereas in the in the lamivudine group there 
was a significant reduction in total cholesterol level at 
week 48 (p=0.044). In regards to renal function, in both 
groups we registered a reduction in estimated glomeru-
lar filtration rate (eGFR), with a median reduction of 8.4 
ml/min in the STR group (p<0.001) and 10.2 mL/min in 
DT (p<0.001). We found a difference in strategy option: 
in a context of side effect and comorbidities, dual ther-
apy strategy was preferred. Conversely, simplification 
and compliance improvement more frequently translat-
ed into a DTG-STR strategy.
Keywords: ARV, cohort studies, dolutegravir, single tab-
let regimen, simplification, HIV, dual therapy.
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n INTRODUCTION
Recent guidelines on treatment of Human Im-munodeficiency Virus (HIV) infection have fo-
cused on the opportunity of reducing the number 
of drugs and/or the number of pills daily given to 
patients [1, 2]. In particular, single-tablet regimens 
(STR) are more frequently prescribed to combine 
the efficacy of a 3-drug regimen and an easier ad-
herence. On the other hand, trials and observation-
al studies demonstrate the efficacy and good tol-
erability of lamivudine (3TC)-based two-drug reg-
imen, both with boosted protease inhibitors (PIs) 
and with dolutegravir (DTG); moreover, the latter 
regimen has shown a favorable effect on metabolic 
profile [3-7]. At this time, no comparisons between 
these two choices of antiretroviral therapy (ART) 
optimization is present in literature; our aim is to 
compare the effectiveness of a DTG-based STR 
with a dual therapy (DT) of lamivudine plus DTG.
n PATIENTS AND METHODS
We evaluated a cohort of HIV-positive, virologi-
cally suppressed (HIV-RNA <50 cps/mL) patients 
switching to 3TC+DTG (DT group) or abacavir/
lamivudine/dolutegravir (STR group) from 8 Ital-
ian centers from 2015 to 2018. Patients with pos-
itive HBsAg at baseline and pts switching from 
abacavir (ABC)/3TC + DTG to ABC/3TC/DTG 
were excluded from analysis. The Kaplan Meier 
method was used to estimate the time to virolog-
ic failure (VF, defined as two consecutive HIV-1 
RNA ≥50 cps/mL in a time frame of three months, 
or a single HIV-1 RNA ≥1,000 cps/mL), and time 
to treatment discontinuation (TD, defined as the 
interruption of any of the study drugs or the reg-
imen intensification), and Cox-regression to eval-
uate predictors of both VF and TD. Censor was 
established at last available visit, death or loss to 
follow-up; when considering the time to VF-anal-
ysis, censor was also established at the time of TD. 
Glomerular filtration rate (eGFR) was estimated 
by the MDRD equation. Changes in immunolog-
ical and metabolic parameters at 48 weeks and 
their predictors were assessed by Student’s T test 
and linear regression analysis, respectively. The 
study was approved by each local Ethics Commit-
tee in all clinical centers (protocol number of the 
coordinating center: 5284/15) and every patient 
signed informed consent before data collection.
n RESULTS 
We analyzed 616 patients, 380 in the STR group 
and 236 in the DT group. Overall median age was 
50.65 years (Interquartile range [IQR] 42.04-56.50), 
449 (72.9%) patients were males; the median time 
from HIV diagnosis was 13.1 years (IQR 6.2-20.1), 
with a median time of ARV exposure of 10.2 years 
(IQR 4.7-17.2) and a median time of virological 
suppression of 58 months (IQR 19-101).
Median CD4+ nadir cell count was 195 cell/mm3 
(IQR 68-303), while median CD4+ cell count at 
baseline was 660 cell/mm3 (IQR 474-866). One 
hundred and eight patients (17.5%) experienced 
at least one virological failure and 14 patients 
(2.3%) had the M184V/I resistance mutation.
Patients in the STR group switched more fre-
quently for simplification (303 of 380, 79.7%), 
while those in the DT group mainly switched for 
simplification (87 of 236, 36.9%), dyslipidemia (73, 
30.9%), other toxicities (52, 22.1%). Full patients’ 
characteristics are summarized in Table 1. 
During an observation time of 387 person-years 
of follow-up (PYFU), with a median follow-up 
time of 13.8 months, we observed 3 VF in the 
STR group, an overall incidence of 0.8 VF per 
100 PYFU. All three failures were due to an HIV-
RNA count >1000 cps/mL; however, all 3 patients 
maintained study regimen and achieved virolog-
ical suppression subsequently in less than three 
months.
In the DT group, we registered 7 VF during 358.6 
PYFU, with an incidence of 1.9 per 100 PYFU. 
Two patients who experienced VF with an HIV-
RNA count >1000 cps/mL did not change their 
regimen and were able to re-achieve suppression 
in a time span of three months. The other 5 pa-
tients failed following two consecutive HIV-RNA 
>50 cps/mL: four of them were intensified to a 
3-drug regimen and another was switched to a 
dual regimen including atazanavir plus DTG; 
all of them achieved virological suppression in a 
similar time span.
Time to VF was not statistically different between 
groups with an estimated probability of maintain-
ing virologic suppression of 99.4% at week 48 in 
the STR group and a probability of 98.2% in the 
DT group (log-rank 0.338). Time to VF was only 
predicted by previous virological failure (vs no 
previous failure, aHR 13.0, 95% Confidence Inter-
val [CI] 2.7-63.0, p=0.001).
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As far as discontinuing the study regimens, 
we found 41 TD during 371.3 PYFU in the STR 
group. Reasons for these interruptions were rep-
resented by neuropsychological events (12 of 380 
cases, 3.1%), gastrointestinal toxicity (9 cases, 
2.4%), musculoskeletal toxicity (2, 0.5%), hyper-
sensitivity reactions (2, 0.5%), other toxicities (5, 
1.3%), concern of cardiovascular risk (4 cases, 
1.1%), other reasons (7 cases, 1.8%: 2 simplifica-
tion to 2-drug regimens, 5 unspecified reasons). 
The estimated probability of remaining in the 
STR group was 90.3% at week 48 and 72.8% at 
week 96. In the DT group, during 369.4 PYFU, 32 
TD occurred; in this group, the estimated proba-
bilities of continuing study treatment were 88.5% 
and 85.4% at weeks 48 and 96, respectively. Rea-
sons for discontinuation were virological failure 
(4 of 236, 1.7%), neuropsychological events (8 cas-
es, 3.3%), gastrointestinal toxicity (6 cases, 2.5%), 
further simplification to STR (3 cases, 1.1%), oth-
er reasons (11 cases, 4.7%: 3 deaths, 2 hypersen-
sitivity reactions, 1 drug-drug interaction and 5 
unspecified reasons). Survival analysis on time to 
TD showed no significative difference between 
Table 1 - Patients’ baseline characteristics.
Variables
Overall
n= 616
3TC-DTG
n= 236
ABC/3TC/DTG 
n=380
p
Females, N (%) 167 (27.1) 61 (25.8) 106 (27.9) 0.641
Age, Years, Median (IQR) 50.6 (42.0-56.5) 51.3 (43.4-56.7) 49.7 (40.5-56.3) 0.035
Risk factor, N (%)
MSM
Eterosexual
IDU
Others
256 (41.6)
234 (38.0)
54 (8.8)
72 (11.7)
93 (39.4)
86 (36.4)
23 (9.7)
34 (14.4)
163 (42.9)
148 (38.9)
31 (8.2)
38 (10.0)
0.320
HCV Ab positive, N (%) 75 (12.2) 34 (14.4) 41 (11.4) 0.313
Years from HIV diagnosis, Median (IQR) 13.1 (6.2-20.1) 14.8 (8.4-20.1) 12.1 (4.8-20.1) 0.043
CDC C, N (%) 175 (28.4) 57 (24.2) 118 (31.4) 0.066
Zenith HIV-RNA, log10, cp/ml, Median (IQR) 4.93 (4.33-5.42) 4.98 (4.42-5.42) 4.91 (4.22-5.40) 0.221
Nadir CD4+, Median (IQR) 195 (68-303) 206 (64-294) 189 (69-311) 0.849
Years on ART, Median (IQR) 10.2 (4.7-17.2) 11.5 (5.5-17.2) 9.6 (3.9-17.3) 0.090
Previous virological failure, N (%) 108 (17.5) 91 (38.5) 17 (4.5) <0.001
Time on virological suppression, Months, Median (IQR) 58.0 (18.7-100.9) 77.2 (35.4-100.3) 43.9 (13.4-101.7) <0.001
CD4+ at baseline (bl), Median (IQR) 660 (474-866) 657 (500-877) 660 (460-861) 0.586
FTC/TDF before switch, N (%) 197 (32.0) 82 (34.7) 115 (30.3) 0.250
ABC/3TC before switch, N (%) 224 (36.4) 33 (14.0) 191 (50.3) <0.001
PIs before switch, N (%) 240 (39.0) 127 (53.8) 113 (29.7) <0.001
DTG before switch, N (%) 150 (24.4) 21 (8.9) 129 (33.9) <0.001
Dual regimen before switch, N (%) 133 (21.6) 108 (45.8) 25 (6.6) <0.001
Discontinuation of previous regimen  
for dyslipidemia, N (%)
89 (14.4) 74 (31.4) 15 (3.9) <0.001
Discontinuation of previous regimen  
for other toxicities, N (%)
97 (15.7) 65 (27.5) 32 (8.4) <0.001
Discontinuation of previous regimen  
for simplification, N (%)
390 (63.3) 87 (36.9) 303 (79.7) <0.001
M184V/I mutation at baseline, N (%):
Present
Absent
Not available
14 (2.3)
557 (90.4)
45 (7.3)
12 (5.1)
203 (86.0)
21 (8.9)
2 (0.5)
354 (93.2)
24 (6.3)
0.363
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study groups (log-rank p=0.846). No predictors 
of TD were found in both groups. 
In a sub-analysis considering only patients 
switching to study regimens for toxicity, we 
found that, in the DT group, the presence of teno-
fovir disoproxil fumarate (TDF) in previous ART 
regimen (aHR 0.11, 95%CI 0.02-0.72, p=0.022) and 
the presence of a PI in the previous regimen (aHR 
0.06, 95%CI 0.01-0.99, p=0.05) resulted inversely 
related to TD; no predictors of TD were found in 
the STR group. No significative differences were 
observed between STR and DT groups regard-
ing time to TD (log-rank p=0.628) in this specific 
sub-analysis. 
Regarding immunological recovery, we observed 
a significant increase in CD4+ cells at week 48 in 
both the STR and the DT group (+47 cell/mm3, 
p=0.017 and +37 cell/mm3, p=0.010, respectively). 
As to the lipid profile, a reduction in the LDL cho-
lesterol levels at week 48 (-2.7 mg/dL, p=0.008) 
had been predicted by the presence of TDF in 
previous ART regimen (B 21.3, 95%CI 2.9-39.0. 
p=0.023) and by the presence of Integrase Inhibi-
tors (INI) in the previous regimen (B 21.7, 95%CI 
1.1-42.8, p=0.039) and it had been reversely as-
sociated with baseline LDL levels (per 1 mg/
dL more, B -0.3, 95%CI -0.4 to -0.2, p<0.001) in 
the STR group. Meanwhile, there was a signifi-
cant reduction in total cholesterol level at week 
48 (-2.0 mg/dL, p=0.044), predicted by presence 
of INI in the previous regimen (B 32.8, 95%CI 
9.2-56.4, p=0.007) and reversely associated with 
baseline level of total cholesterol (per 1 mg/dL 
more, B -0.5, 95%CI -0.7 to -0.3, p<0.001) in the 
DT group.
In regard to renal function, we registered a sig-
nificant reduction in the estimated glomeru-
lar filtration rate (eGFR) in both groups: medi-
an reduction of 8.4 mL/min in the STR group 
(p<0.001) and 10.2 mL/min in the 3TC group 
(p<0.001). This difference between the two 
groups was statistically significant (p=0.006). In 
the STR group, male sex (vs female sex, mean dif-
ference in change -7.9 mL/min, 95%CI -13.5 to 
-2.2, p=0.007) and baseline eGFR (per 1 mL/min 
more, -0.4 ml/min, 95%CI -0.5 to -0.4) predicted 
a more pronounced decrease in eGFR. Whereas, 
switching from a DTG-containing regimen was 
reversely associated with eGFR deterioration 
(+7.9 mL/min, 95%CI 2.5-13.4, p=0.005). Base-
line MDRD (-0.3, 95%CI -0.4 to -0.2, p<0.001) 
and switching from a FTC/TDF-based regimen 
(vs other backbone, -20.2, 95%CI -36.1 to -4.4, 
p=0.013) had been the 2 factors which predict-
ed a more pronounced reduction of the eGFR at 
week 48 in the DT group.
n DISCUSSION
In our multicenter cohort, both simplification 
strategies showed similar effectiveness and high 
tolerability. In the STR group, 3 patients experi-
enced VF but all of them maintained study reg-
imen and rapidly re-achieved viral suppression; 
also, the 7 patients experiencing VF in the DT 
group were able to regain viral suppression in 
less than three months, with 2 of them maintain-
ing study regimen and 1 of them switching to an-
other DTG-based 2-drug regimen. These data are 
encouraging, particularly for the 2-drug regimen 
group, and are probably to be due to the high ge-
netic barrier to resistance of dolutegravir [8]. 
There was no difference in the causes of discontin-
uation between groups, with an incidence of TD 
inferior to 12 per 100 PYFU in both of them. Neu-
ropsychological events were rare in our cohort 
and the rate of discontinuation for neurological 
toxicity was similar between groups, apparently 
in contrast with other studies showing a higher 
risk of CNS toxicity in DTG-based regimens con-
taining abacavir [9]. 
Although 3 patients in the STR group, discontin-
ued following concerns of cardiovascular disease, 
it is to be noted that no cardiovascular adverse 
events occurred during observation period in 
patients taking abacavir [10]. Moreover, both reg-
imens showed an improvement in blood lipids’ 
levels, a common finding in DTG-based simplifi-
cation regimens [11].
Lastly, we found a significant decrease of eGFR 
with both regimens, with a more pronounced de-
crease in the DT group. However, it is to be not-
ed that no patient in the 3TC group discontinued 
the regimen for eGFR decline. These findings are 
consistent with previous works describing the 
apparent decline in eGFR in patients taking DTG, 
probably due to the inhibition of the renal protein 
organic cation transporter 2 [12]. 
Limitations of our study include the retrospec-
tive design and the possibility of study bias due 
to differences in patients’ baseline characteristics 
between groups. 
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n CONCLUSIONS
In our multicenter cohort, both simplification 
strategies showed similar effectiveness and high 
tolerability; in our clinical practice setting, we 
found a difference in strategy option: indeed, in a 
contest of side effect and comorbidities, dual ther-
apy strategy was preferred. Conversely, simpli-
fication and compliance improvement more fre-
quently translated into a DTG-STR strategy [11]. 
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